HIFU - High-Intensity Focused Ultrasound Therapy

Therapy | Treatment

HIFU - High-Intensity Focused
Ultrasound Therapy

For the treatment for cancer and other
diseases using high-intensity focused
ultrasound (HIFU).

MechanismSafetyTreatmentIndicationsCost |

What is HIFU?

HIFU is a cutting edge treatment that results in necrosis of cancer tissue after applying high-intensity focused ultrasound (HIFU) energy to a focused area with the action of thermal energy and cavitation.

For a long time, ultrasound has been playing an important role in diagnosis, but these days it's role has also expanded to include treatment. With the advancement of imaging technology, HIFU makes highly effective to destroy migrating cancer cells without surgery. Therefore, HIFU can be considered as ultrasonic version of three dimentional radiation such as cyber knife and gamma knife.


Ultrasound-guided 3rd generation FEP-BY02 HIFU Tumor Therapy System

HIFU treatment device was first developed for transrectal ultrasound biopsy. And then the new treatment has been experimenting from outside the body by HIFU. In our clinic, we use the Ultrasound-guided 3rd generation FEP-BY02 HIFU Tumor Therapy System.


Using the ultrasound imagining part of the HIFU device it is possible to observe damaged areas in real time. This ability can also make follow-up screening easy and it is considered a big benefit that the damaged areas in abdominal organs, which are usually in motion, can be easily screened.

Our FEP‐BY02 HIFU is a fixed focus device focusing 251 ultrasonic transmission elements at 1.1 MHz lined up on 37 cm spherical body.

Many of HIFU is applied only from below whereas the HIFU which our clinic uses is possible to be applied both from above and below by using two devices.

For liver cancer and pancreatic cancer, it is actually applied about 99 % from above in order to be treated highly precisely. It takes time to treat and it is also difficult to target the area if applied only from below.

Mechanism of the treatment

HIFU is a medical procedure which focuses ultrasound with high intensity inside of the body which results in necrosis of cancer tissue by way of thermal energy and cavitation.

HIFU destroys the size with 3 mm x 3 mm x 10 mm of cancer cells by a few second single dose irradiation which is generated by thermal energy on the targetted area.

The area which is irradiated by a single dose is limited to 3 mm x 3 mm x 10 mm.

Repositioning and repeated irradiation is used to cover a larger area to destroy all of the tumor area. The cancer cells are destroyed by repeatedly being irradiated.


Biological action

There are two biological actions produced in the patient's body - thermal effect and non-thermal effect.


Thermal Effect

When ultrasound with the temperature of over 60 °C (140 °F) is applied to cancer cells for a few seconds, the cancer tissue will be coagulated and destroyed.


Non-thermal effect

Ultrasound also generates a non-thermal effects which is called cavitation. Cavitation is the phenomenon by which air bubbles are generated when ultrasound is spotted. The shock wave generated when air bubbles burst or micro jet stream is also considered to kill cancer cells.

Safety


Radiation exposure

The energy level of HIFU is about 1000 times as big as ultrasound device for imaging. But compared to proton beam, x-ray or CT, it is extremely low and so it is said to be fairly safe. And there is no worry about radiation exposure.


Skin burn

The targeted area by a single irradiation is only limited to 3 mm x 3 mm x 10 mm. If there are cancer cells in the internal organ near the skin, it will cause skin burn due to skin temperature raised. So our FEP‐BY02 HIFU adopts the transducer with large diameter, and the safety is enhanced by widening the angle of incidence by 80 degrees.

Treatment

In general, it takes about 1 hour and 30 minutes for a single treatment, which is performed 1 or 2 times.

Anaesthetic is not usually applied. This is a treatment uses ultrasound energy, so there is no limitation as with the use of radiation. HIFU treatment can be used repeatedly because there is no risk of radiation exposure.

Depending on the size and location of the cancer, various treatment will be examined, and generally, hospitalization is not required. But the contents of treatment, the dose and the need for hospitalization will vary depending on each patient's medical condition.

HIFU treatment indications

  • Uterine fibroids (Myoma)
  • Liver cancer
  • Metastatic liver tumors
  • Breast cancer
  • Kidney cancer
  • Pancreatic cancer
  • Prostate cancer
  • Soft tissue sarcoma
  • Bone tumors
  • Others indications

The significance of HIFU treatment for Hepatocellular carcinoma (HCC)

The significant use of Gd-EOB-DAPT MRI has enabled us to detect Hepatocellular carcinoma (HCC), the most common type of liver cancer, at earlier stage, which used to be difficult to be detected with dynamic CT. So the prompt measures for the treatment are being required. Under the circumstances, HIFU has made it possible to treat a patient with liver cancer of 1-2 cm big for about 1 hour without hospitalization. HIFU will be considered to be one of the leading treatments for HCC in Japan.

Cost of HIFU treatment

Number of treatments: 1 or more

  • 1 treatment - 648,000 yen

  • 2 treatments - 1,296,000 yen

  • HIFU treatment is available at Saisei Mirai Kobe Clinic.
  • The exact treatment protocol will vary slightly between patients and will be customized to each individual patient by the doctor.

Treatments commonly used in conjunction with HIFU

GcMAF therapy
High Dose GcMAF therapy
Maitake MD-fraction
Maitake MD-fraction
Hyperbaric oxygen therapy
Hyperbaric oxygen therapy
Ozone therapy
Ozone therapy

News

Heart Pharmacy website gcmaf.co.jp is now open

Purchase your Colostrum MAF here using PayPal or credit card.

Heart Pharmacy website


2016 Integrative Medical Therapies Conference - Osaka, Japan

Thank you very much for your participation at the Saisei Mirai 2016 Integrative Medical Therapies conference in Osaka, held on Sunday 13th November 2016.

2016 Integrative Medical Therapies conference - Osaka, Japan


Genostics Conference - Sydney, Australia

24-SEP-2016
Dr Toshio Inui

Genostics official website


Symposium on Integrated Medicine: Electric Fields Therapy & Immunotherapy - Jakarta, Indonesia


22-JUL-2016
Dr. Toshio Inui gave a presentation of the electric field therapy and second-generation GcMAF and colostrum MAF at a conference which was held in Jakarta, Indonesia on July 22, 2016.



International Pharmacy Conference

14 to 15-JUL-2016
Dr. Shinichiro Akiyama at International Pharmacy Conference, which was held in the United States Philadelphia, Pennsylvania on July 14 to 15, 2016, the Clinical experience of colostrum derived protein against solid cancer has been announced as the Keynote Speaker.



New New research papers published by Saisei Mirai in Anticancer Research available online.

Research paper
2016 Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis (PDF)
ANTICANCER RESEARCH 36: 3771-3774 (2016)

Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis

Research paper
2016 Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields (PDF)
ANTICANCER RESEARCH 36: 3767-3770 (2016)

Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields

Research paper
2016 Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors (PDF)
ANTICANCER RESEARCH 36: 3619-3624 (2016)

Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors

New research papers published by Saisei Mirai in Anticancer Research available online.

New research papers on Oral Colostrum GcMAF for Chronic Fatigue Syndrome (CFS) and serious infection published in Anticancer Research journal.

Research paper
2015 Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports (PDF)
Anticancer Res August 2015 35 (8) 4545-4549

Conference presentation - 10th International Congress for Medical Laser Applications, Germany

13-JUN-2015
Clinical application of Second Generation GcMAF and oral GcMAF
Dr Toshio Inui

Clinical application of Second Generation GcMAF and oral GcMAF
ISLA website

Conference presentation - 9th International Congress for Medical Laser Applications, Germany

29-JUN-2014
Indications for GcMAF for immunotherapy of cancers and chronic viral and bacterial infections (PDF)

Dr Toshio Inui

Dr Toshio Inui Indications for GcMAF for immunotherapy of cancers and chronic viral and bacterial infections

Conference presentation - The 17th Annual Meeting of The Society of Biotherapeutic Approaches, Fukuoka University

7-DEC-2013
Case Report: A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy (PDF), PPT

Dr Toshio Inui

Dr Toshio Inui Case Report - A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy

New research papers published by Saisei Mirai in Anticancer Research available online.

New research papers on GcMAF and integrative cancer immunotherapy treatment written in collaboration with the University of Tokushima, Kanazawa University and Kobe University Graduate School of Medicine researchers and Saisei Mirai published in Anticancer Research journal.

Research paper
2013 Degalactosylated/Desialylated Human Serum Containing GcMAF Induces Macrophage Phagocytic Activity and In Vivo Antitumor Activity (PDF)
Anticancer Res July 2013 33 (7) 2881-2885

Cancer vaccine therapy - autologous tissue derived tumor vaccine Cancer vaccine therapy - autologous tissue derived tumor vaccine Cancer vaccine therapy - autologous tissue derived tumor vaccine

Research paper
2013 Clinical Experience of Integrative Cancer Immunotherapy with GcMAF (PDF)
Anticancer Res July 2013 33 (7) 2917-2919

Cancer vaccine therapy - autologous tissue derived tumor vaccine Cancer vaccine therapy - autologous tissue derived tumor vaccine Cancer vaccine therapy - autologous tissue derived tumor vaccine

Nature Outlook sponsored article

For more details on GcMAF see our GcMAF page.



Experiment report of Gc MAF stability assay
14-JUN-2012 Stability of GcMAF in Serum (PDF)
H Mukai, Y Uto. Department of Biological Science and Technology, The University of Tokushima.

Stability of GcMAF in Serum report Stability of GcMAF in Serum report

The results show that 2nd Generation GcMAF is stable for 1 year at 4 °C, for 14 days at room temperature (around 20 °C), and for 7 days at 40 °C.

See Research and references for more details on experiments on macrophage phagocytic activity and stability of our GcMAF.


Collaborations with the University of Tokushima
We collaborate with GcMAF researchers at the University of Tokushima, Japan in the development of second generation GcMAF. See Research and references for published research papers on Gc-MAF in peer-reviewed scientific journals authored by the University of Tokushima researchers over the last decade. Our research on GcMAF is ongoing and papers are being prepared for publication in collaboration between the University of Tokushima and Saisei Mirai in the next few months.


University of Tokushima, Institute of Technology and Science, Laboratory Research

Our research group:
Contact us
Treatments and therapies
Contact us

Saisei Mirai Clinics
Kobe Saisei Mirai Clinic
  • Cancer
  • Skin regeneration
  • Skin rejuvenation
  • Anti-aging
Kobe Saisei Mirai Clinic

Boeki Center Building
23rd Floor
5-1-14 Hamabetori Chuo-ku
Kobe-shi
Hyogo-ken 651-0083
Japan


Inui Cancer
Immunotherapy Clinic
  • Cancer
  • Hepatitis
  • Chronic diseases
Inui Cancer Immunotherapy Clinic

6-14-17 Kindachou
Moriguchi-shi
Osaka 570-0011
Japan
TEL: +81 (0)6-6902-5251
FAX: +81 (0)6-6902-7133

Inui Cancer Immunotherapy Clinic

Keihan Clinic
  • Cancer
  • Hepatitis
  • Chronic diseases
  • Anti-aging
Saisei Mirai Keihan Clinic

Nature 21 Building
2nd Floor
3-34-8 Okubo-cho
Moriguchi-shi
Osaka 570-0012
Japan
TEL: +81 (0)6-6902-1001


R Future Cancer Int'l Clinic
  • Cancer
R Future Cancer Int'l Clinic

ORE Hiroo Building
7th Floor
5-10-26 Minamiazabu
Minato-ku
Tokyo-to 106-0047
Japan


R Science Clinic
  • Skin regeneration
  • Skin rejuvenation
  • Anti-aging
R Mirai Clinic

ORE Hiroo Building
6th Floor
5-10-26 Minamiazabu
Minato-ku
Tokyo-to 106-0047
Japan


Immunotherapy Lab
  • Cell Processing Center
Immunotherapy Lab

Nature 21 Building
3rd Floor
3-34-8 Okubo-cho
Moriguchi-shi
Osaka 570-0012
Japan